Leo Pharma Us

Leo Pharma Us company information, Employees & Contact Information

Explore related pages

Related company profiles:

LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. For more information, visit www.leo-pharma.us and follow us on Twitter @LEOPharmaUS. Disclaimer: This site is intended for discussions about LEO Pharma US and the various initiatives LEO Pharma US is involved in. Due to regulations, discussions about pharmaceutical products are not allowed on this channel. All content must be factual and non-promotional. LEO Pharma US reserves the right to moderate or remove any content that may be inconsistent with legislation, industry ethics and regulations and LEO Pharma US’ values, including: - Profane or vulgar language - Insulting or offensive comments, such as displays of racism, calls to violence, hate propaganda, etc. - Commercial or political advertising - Copyright infringements, or any violation of the rights of external parties - automatically-generated content i.e. spam - Wrong/false statements For more information about our social media principles, please visit https://leo-pharma.com/social-media-principles To view our privacy policy, go to https://www.leo-pharma.us/Home/Privacy.aspx

Company Details

Employees
43
Founded
-
Address
Madison, New Jersey , Us
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Keywords
Dermatology.
HQ
Madison, New Jersey
Looking for a particular Leo Pharma Us employee's phone or email?

Leo Pharma Us Questions

News

LEO Pharma Unveils Data on the U.S. Prevalence of Chronic Hand Eczema at Fall Clinical Dermatology Conference - BioSpace

LEO Pharma Unveils Data on the U.S. Prevalence of Chronic Hand Eczema at Fall Clinical Dermatology Conference BioSpace

Leo posts strong sales growth in US, with more to come from hand eczema drug Anzupgo - Fierce Pharma

Leo posts strong sales growth in US, with more to come from hand eczema drug Anzupgo Fierce Pharma

Leo Pharma is one step closer to its 2025-goal – CEO sees no obstacles on the road to the stock market - medwatch.com

Leo Pharma is one step closer to its 2025-goal – CEO sees no obstacles on the road to the stock market medwatch.com

FDA Approves LEO Pharma's Delgocitinib for Adults With Moderate to Severe Chronic Hand Eczema - Dermatology Times

FDA Approves LEO Pharma's Delgocitinib for Adults With Moderate to Severe Chronic Hand Eczema Dermatology Times

FDA green light for LEO’s Anzupgo - The Pharma Letter

FDA green light for LEO’s Anzupgo The Pharma Letter

ANZUPGO® (delgocitinib) Cream Is Now the First and Only FDA-Approved Treatment for Moderate-to-Severe Chronic Hand Eczema (CHE) in Adults - Business Wire

ANZUPGO® (delgocitinib) Cream Is Now the First and Only FDA-Approved Treatment for Moderate-to-Severe Chronic Hand Eczema (CHE) in Adults Business Wire

US FDA approves first hand eczema treatment: Leo Pharma’s Anzupgo - BioWorld MedTech

US FDA approves first hand eczema treatment: Leo Pharma’s Anzupgo BioWorld MedTech

LEO Pharma’s eczema cream is approved in the US; Abivax’s $650M offering - Endpoints News

LEO Pharma’s eczema cream is approved in the US; Abivax’s $650M offering Endpoints News

Leo roars to key FDA nod for Anzupgo to treat chronic hand eczema - Fierce Pharma

Leo roars to key FDA nod for Anzupgo to treat chronic hand eczema Fierce Pharma

LEO Pharma Announces FDA Approval of ANZUPGO® (delgocitinib) Cream in the U.S. - BioSpace

LEO Pharma Announces FDA Approval of ANZUPGO® (delgocitinib) Cream in the U.S. BioSpace

Leo Pharma CEO: Phone ringing off the hook since big deals with Gilead and Boehringer - medwatch.com

Leo Pharma CEO: Phone ringing off the hook since big deals with Gilead and Boehringer medwatch.com

Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases - Business Wire

Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases Business Wire

Leo Pharma receives US approval for “growth driver” eczema treatment - medwatch.com

Leo Pharma receives US approval for “growth driver” eczema treatment medwatch.com

LEO Pharma Announces Publication of Head-to-Head DELTA FORCE Study Results in The Lancet - BioSpace

LEO Pharma Announces Publication of Head-to-Head DELTA FORCE Study Results in The Lancet BioSpace

Leo Pharma finds derms want better chronic hand eczema meds - Fierce Pharma

Leo Pharma finds derms want better chronic hand eczema meds Fierce Pharma

Leo Pharma maintains IPO pursuit - medwatch.com

Leo Pharma maintains IPO pursuit medwatch.com

LEO Pharma Survey: Dermatology Providers Say Chronic Hand Eczema Is Widely Misunderstood and Inadequately Managed - BioSpace

LEO Pharma Survey: Dermatology Providers Say Chronic Hand Eczema Is Widely Misunderstood and Inadequately Managed BioSpace

Leo Pharma will stay calm after acquisition and approval: "Don't expect news like this every two weeks" - medwatch.com

Leo Pharma will stay calm after acquisition and approval: "Don't expect news like this every two weeks" medwatch.com

Leo Pharma CSO comments on closure of research department after its new agreement with contract researchers - medwatch.com

Leo Pharma CSO comments on closure of research department after its new agreement with contract researchers medwatch.com

CEO after billion-dollar deal: "It will go down in Leo Pharma history" - medwatch.com

CEO after billion-dollar deal: "It will go down in Leo Pharma history" medwatch.com

Leo Pharma in billion-dollar deal with US pharmaceutical giant - medwatch.com

Leo Pharma in billion-dollar deal with US pharmaceutical giant medwatch.com

NIH leaders join health agency exodus—Chutes & Ladders - Fierce Biotech

NIH leaders join health agency exodus—Chutes & Ladders Fierce Biotech

FDA Accepts LEO Pharma’s Filing of Delgocitinib Cream New Drug Application for the Treatment of Chronic Hand Eczema - National Eczema Association

FDA Accepts LEO Pharma’s Filing of Delgocitinib Cream New Drug Application for the Treatment of Chronic Hand Eczema National Eczema Association

After transformation under new CEO, Leo Pharma touts innovation model and financial progress - Fierce Pharma

After transformation under new CEO, Leo Pharma touts innovation model and financial progress Fierce Pharma

Leo Pharma’s Timber bet falls flat following Phase III failure - Pharmaceutical Technology

Leo Pharma’s Timber bet falls flat following Phase III failure Pharmaceutical Technology

Leo Pharma tells doctors to 'Talk to the Hand' in new dermatology campaign - Fierce Pharma

Leo Pharma tells doctors to 'Talk to the Hand' in new dermatology campaign Fierce Pharma

Leo Pharma Announces US Availability of Tralokinumab Single-Dose Autoinjector - HCPLive

Leo Pharma Announces US Availability of Tralokinumab Single-Dose Autoinjector HCPLive

Solid Start to the Year: LEO Pharma Delivers 13% Revenue Growth Driven by Strong Performance in Dermatology - Business Wire

Solid Start to the Year: LEO Pharma Delivers 13% Revenue Growth Driven by Strong Performance in Dermatology Business Wire

LEO Pharma's Tralokinumab-ldrm Autoinjector Now Available in US for Adults With Moderate to Severe Atopic Dermatitis - Dermatology Times

LEO Pharma's Tralokinumab-ldrm Autoinjector Now Available in US for Adults With Moderate to Severe Atopic Dermatitis Dermatology Times

LEO Pharma’s Robert Spurr on Delgocitinib Cream’s Approval and the Future of Chronic Hand Eczema - Dermatology Times

LEO Pharma’s Robert Spurr on Delgocitinib Cream’s Approval and the Future of Chronic Hand Eczema Dermatology Times

On heels of Gilead deal, Leo pays Boehringer Ingelheim €90 million up front for Spevigo - Fierce Pharma

On heels of Gilead deal, Leo pays Boehringer Ingelheim €90 million up front for Spevigo Fierce Pharma

Leo Pharma completes acquisition of Timber Pharmaceuticals - medwatch.com

Leo Pharma completes acquisition of Timber Pharmaceuticals medwatch.com

LEO Pharma Reinforces Leadership in Medical Dermatology with New Data from Across Its Portfolio at 2025 Fall Clinical Dermatology Conference - BioSpace

LEO Pharma Reinforces Leadership in Medical Dermatology with New Data from Across Its Portfolio at 2025 Fall Clinical Dermatology Conference BioSpace

LEO Pharma and ICON partner for clinical trial execution in dermatology - Clinical Trials Arena

LEO Pharma and ICON partner for clinical trial execution in dermatology Clinical Trials Arena

LEO Pharma’s Monica Shaw on access to medicine challenges - European Medical Journal

LEO Pharma’s Monica Shaw on access to medicine challenges European Medical Journal

Delgocitinib (Anzupgo) Scores FDA Approval for Chronic Hand Eczema - HCPLive

Delgocitinib (Anzupgo) Scores FDA Approval for Chronic Hand Eczema HCPLive

Boehringer Ingelheim Pharmaceuticals, Inc. Welcomes Brian Hilberdink as President, U.S. Human Pharma - PR Newswire

Boehringer Ingelheim Pharmaceuticals, Inc. Welcomes Brian Hilberdink as President, U.S. Human Pharma PR Newswire

Boehringer Ingelheim Names Brian Hilberdink as President, U.S. Human Pharma - Contract Pharma

Boehringer Ingelheim Names Brian Hilberdink as President, U.S. Human Pharma Contract Pharma

Leo Pharma meets big 2023 goal but substantial deficit remains - medwatch.com

Leo Pharma meets big 2023 goal but substantial deficit remains medwatch.com

More layoffs at Leo Pharma: 200 jobs to be cut - medwatch.com

More layoffs at Leo Pharma: 200 jobs to be cut medwatch.com

LEO’s Anzupgo granted FDA approval to treat moderate-to-severe chronic hand eczema - PMLiVE

LEO’s Anzupgo granted FDA approval to treat moderate-to-severe chronic hand eczema PMLiVE

Leo Pharma prepares to come for the topical JAK market as Incyte's Opzelura cream launch cools off - Fierce Pharma

Leo Pharma prepares to come for the topical JAK market as Incyte's Opzelura cream launch cools off Fierce Pharma

Leo’s single-dose autoinjector secures FDA approval for atopic dermatitis - Pharmaceutical Technology

Leo’s single-dose autoinjector secures FDA approval for atopic dermatitis Pharmaceutical Technology

Leo Pharma gets green light from FDA for Adbry autoinjector - medwatch.com

Leo Pharma gets green light from FDA for Adbry autoinjector medwatch.com

Leo Looks To Grow In US After Hand Eczema Cream Approval - Citeline News & Insights

Leo Looks To Grow In US After Hand Eczema Cream Approval Citeline News & Insights

Two Major Regulatory Milestones Announced for Delgocitinib for CHE - Dermatology Times

Two Major Regulatory Milestones Announced for Delgocitinib for CHE Dermatology Times

Leo acquisition negotiated with four suitors while struggling to survive - medwatch.com

Leo acquisition negotiated with four suitors while struggling to survive medwatch.com

Leo Pharma owners about an IPO in 2026: "A realistic possibility" - medwatch.com

Leo Pharma owners about an IPO in 2026: "A realistic possibility" medwatch.com

LEO Pharma’s FDA nod adds a challenger to Dupixent’s dominance in eczema - MedCity News

LEO Pharma’s FDA nod adds a challenger to Dupixent’s dominance in eczema MedCity News

New appointment at Chiesi USA - The Pharma Letter

New appointment at Chiesi USA The Pharma Letter

Cara chief hands keys to former Leo head Posner months after first approval in its 17-year history - Fierce Biotech

Cara chief hands keys to former Leo head Posner months after first approval in its 17-year history Fierce Biotech

The Top 25 Healthcare Technology Leaders of New Jersey for 2023 - The Healthcare Technology Report.

The Top 25 Healthcare Technology Leaders of New Jersey for 2023 The Healthcare Technology Report.

LEO Pharma bets on AI to find the next skin-care breakthrough - Computing UK

LEO Pharma bets on AI to find the next skin-care breakthrough Computing UK

Leo Pharma will retain thrombosis business despite goal to focus on dermatology - medwatch.com

Leo Pharma will retain thrombosis business despite goal to focus on dermatology medwatch.com

Leo Pharma owner: "You can’t go public without a growth outlook or an interesting pipeline" - medwatch.com

Leo Pharma owner: "You can’t go public without a growth outlook or an interesting pipeline" medwatch.com

Leo Pharma to reuse model from failed acquisition - medwatch.com

Leo Pharma to reuse model from failed acquisition medwatch.com

Ex-Sanofi executive to head up translational medicine at LEO Pharma - Fierce Biotech

Ex-Sanofi executive to head up translational medicine at LEO Pharma Fierce Biotech

LEO Pharma’s azelaic acid foam for rosacea now available - Dermatology Times

LEO Pharma’s azelaic acid foam for rosacea now available Dermatology Times

Leo Pharma appoints new CFO - medwatch.com

Leo Pharma appoints new CFO medwatch.com

FDA Approves First Cream for Treating Chronic Hand Eczema - U.S. News & World Report

FDA Approves First Cream for Treating Chronic Hand Eczema U.S. News & World Report

LEO Pharma A/S appoints Brian Hilberdink new President of LEO Pharma Inc. United States - Via Ritzau

LEO Pharma A/S appoints Brian Hilberdink new President of LEO Pharma Inc. United States Via Ritzau

GILEAD AND LEO PHARMA ENTER INTO STRATEGIC PARTNERSHIP TO ACCELERATE DEVELOPMENT OF ORAL STAT6 PROGRAM WITH POTENTIAL IN MULTIPLE INFLAMMATORY DISEASES - Via Ritzau

GILEAD AND LEO PHARMA ENTER INTO STRATEGIC PARTNERSHIP TO ACCELERATE DEVELOPMENT OF ORAL STAT6 PROGRAM WITH POTENTIAL IN MULTIPLE INFLAMMATORY DISEASES Via Ritzau

KemPharm Appoints Christopher Posner As Independent Director - citybiz

KemPharm Appoints Christopher Posner As Independent Director citybiz

Leo’s Adbry approved by FDA for atopic dermatitis - BioWorld MedTech

Leo’s Adbry approved by FDA for atopic dermatitis BioWorld MedTech

LEO Pharma signs agreement to acquire Timber Pharmaceuticals - Via Ritzau

LEO Pharma signs agreement to acquire Timber Pharmaceuticals Via Ritzau

LEO Pharma Inc. Debuts LEO(R) Quality Care Program for Plaque Psoriasis Patients - Fierce Pharma

LEO Pharma Inc. Debuts LEO(R) Quality Care Program for Plaque Psoriasis Patients Fierce Pharma

LEO Pharma announces FDA approval of Adbry™ (tralokinumab) as the first and only treatment specifically targeting IL-13 for adults with moderate-to-severe atopic dermatitis - ANTARA News

LEO Pharma announces FDA approval of Adbry™ (tralokinumab) as the first and only treatment specifically targeting IL-13 for adults with moderate-to-severe atopic dermatitis ANTARA News

Taclonex Receives FDA Approval for Body Plaque Psoriasis - Fierce Pharma

Taclonex Receives FDA Approval for Body Plaque Psoriasis Fierce Pharma

Picato Gel Approved for Actinic Keratoses - Medical Professionals Reference

Picato Gel Approved for Actinic Keratoses Medical Professionals Reference

Top Leo Pharma Us Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant